

Craven House Capital PLC

10 September 2024

**Certain information contained within this Announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 ("MAR") as applied in the United Kingdom. Upon publication of this Announcement, this information is now considered to be in the public domain.**

**Craven House Capital plc**

("Craven House" or the "Company")

**Investee company update: RoseMonkey Ltd**

The Company confirms that RoseMonkey Ltd (a company in which Craven has a 24.4% shareholding in) has notified it that it has sold certain IP rights and participated in a financing transaction with Quiapeg Pharma AB ("QuiaPeg").

Following completion of the transactions, RoseMonkey was awarded 1,416,007,811 shares in QuiaPeg. RoseMonkey elected to distribute a proportionate amount of those shares to Craven House.

Craven House has therefore received 345,505,096 shares representing 23.2% of QuiaPeg and a market value of approximately 758,792 as at September 9<sup>th</sup>, 2024.

QuiaPeg is a drug development company based on a patented drug delivery platform, Uni-Oleaver®, and the company develops improved and patentable forms of drugs under development or already approved by regulatory authorities. QuiaPEGs shares are admitted to trading on Nasdaq First North Growth Market.

Craven House remains a 24.4% shareholder in RoseMonkey Ltd.

For further information please contact:

**Craven House Capital Plc**

**Tel: 0203 286 8130**

Mark Pajak

[www.Cravenhousecapital.com](http://www.Cravenhousecapital.com)

**SI Capital**

**Tel: 01483 413500**

**Broker**

Nick Emerson

[www.sicapital.co.uk](http://www.sicapital.co.uk)

**SPARK Advisory Partners Limited**

**Tel: 0203 368 3550**

**Nominated Adviser**

Matt Davis

[www.Sparkadvisorypartners.com](http://www.Sparkadvisorypartners.com)

**About Craven House Capital:**

The Company's Investing Policy is primarily to invest in or acquire a portfolio of companies, partnerships, joint ventures, businesses or other assets participating in the e-Commerce sector.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@lseg.com](mailto:ms@lseg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

UPDEAFNNEASLEAA